Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take the study medication improve compared to patients who take a placebo (sugar pill).

Secondary:The study will also evaluate the blood levels of the study medication, AVE1625 in patients who join the study.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi

Criteria

Inclusion Criteria:

• The diagnosis of Alzheimer's disease

• Recent brain image(Computerized Axial Tomographic Scan -CAT scan or Magnetic Resonance Imaging - MRI)

• Mild to moderate range of disease; not too severe

Exclusion Criteria:

• Severe or unstable medical diseases

• Neurological disorder other than Alzheimer's disease

• Depression that is not well controlled

• Treatment with memantine

• Inpatient in a total care facility (e.g.: Nursing home)

• Lack of reliable caregiver